A pooled long-term follow-up after radiotherapy for prostate cancer with and without a rectal hydrogel spacer: impact of hydrogel on decline in sexual quality of life.
prostate
quality of life
radiation
rectal spacer
sexual function
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
06
2023
accepted:
27
07
2023
medline:
27
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
The purpose of this study was to analyze the impact of prostate rectal spacers on sexual quality of life (QOL) following external beam radiation therapy (RT). Patient- reported QOL was evaluated using the Expanded Prostate Cancer Index Composite (EPIC). Patients were pooled from two sources: a randomized controlled trial and a non-randomized cohort of patients from a single institution. Both cohorts used the same spacing product and QOL instrument. Analysis was limited to those with good baseline pre-treatment sexual QOL (EPIC >/= 60). Differences in QOL summary score and individual items were assessed compared with baseline and between treatment arms. A total of 128 men had good baseline sexual function and were evaluated (64% with spacer and 36% without) with QOL data available for median 33 months (range: 2.5-69.4 months). Men without spacer were more likely to have declines in sexual function ( In this pooled analysis of QOL after prostate RT, the utilization of a hydrogel spacer was associated with better sexual QOL, less men with measurable declines in sexual QOL, and higher rates of adequate erectile function.
Identifiants
pubmed: 37886176
doi: 10.3389/fonc.2023.1239104
pmc: PMC10599244
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1239104Informations de copyright
Copyright © 2023 Seymour, Pinkawa, Daignault-Newton, Bosch, Michalski, Gay and Hamstra.
Déclaration de conflit d'intérêts
ZS – Augmenix has provided grant for dosimetric analysis unrelated to the current study. DH and SD-N as consultant for Augmenix unrelated to the current study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S130-4
pubmed: 20171507
Qual Life Res. 2005 Mar;14(2):285-95
pubmed: 15892420
Urology. 2015 Jan;85(1):101-5
pubmed: 25530370
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):20-31
pubmed: 15629590
J Clin Oncol. 2017 Jul 10;35(20):2306-2314
pubmed: 28493812
Pract Radiat Oncol. 2018 Jan - Feb;8(1):e7-e15
pubmed: 28951089
N Engl J Med. 2023 Apr 27;388(17):1547-1558
pubmed: 36912538
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
BJU Int. 2018 Jan;121(1):61-68
pubmed: 28710895
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8
pubmed: 24113055
Br J Radiol. 2017 Oct;90(1078):20160877
pubmed: 28749171
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):374-377
pubmed: 28871986
Pract Radiat Oncol. 2017 May - Jun;7(3):195-202
pubmed: 28089528
Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1074-1084
pubmed: 36566906
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
Cancer. 2008 Jan 1;112(1):61-8
pubmed: 18040996
BMC Med Inform Decis Mak. 2021 Dec 31;21(1):374
pubmed: 34972513
Radiother Oncol. 2013 Aug;108(2):306-13
pubmed: 23849168
JAMA Oncol. 2023 Apr 1;9(4):511-518
pubmed: 36757690
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-985
pubmed: 28209443
Eur Urol. 2017 Oct;72(4):617-624
pubmed: 28233591
Clin Transl Radiat Oncol. 2019 Dec 31;21:77-84
pubmed: 32072028
Radiother Oncol. 2015 Aug;116(2):179-84
pubmed: 26276528
JAMA. 2011 Sep 21;306(11):1205-14
pubmed: 21934053
Radiother Oncol. 2020 Jan;142:62-71
pubmed: 31767473